Australia markets closed

Arena Pharmaceuticals, Inc. (ARNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
71.25+0.67 (+0.95%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close70.58
Open71.16
Bid70.79 x 900
Ask71.99 x 1300
Day's range69.47 - 72.30
52-week range32.95 - 72.30
Volume889,955
Avg. volume549,395
Market cap4.107B
Beta (5Y monthly)1.27
PE ratio (TTM)N/A
EPS (TTM)-6.82
Earnings date05 Nov 2020 - 09 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est83.23
  • How Much is Arena Pharmaceuticals' (NASDAQ:ARNA) CEO Getting Paid?
    Simply Wall St.

    How Much is Arena Pharmaceuticals' (NASDAQ:ARNA) CEO Getting Paid?

    Amit Munshi became the CEO of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in 2016, and we think it's a good time to look...

  • What Kind Of Shareholders Own Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)?
    Simply Wall St.

    What Kind Of Shareholders Own Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)?

    If you want to know who really controls Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), then you'll have to look at the...

  • Here's Why Arena Pharmaceuticals Jumped Higher Today
    Motley Fool

    Here's Why Arena Pharmaceuticals Jumped Higher Today

    Shares of Arena Pharmaceuticals (NASDAQ: ARNA) are up 13% at 2:13 p.m. EDT because its rival, Bristol Myers Squibb (NYSE: BMY), reported positive data on Zeposia in patients with ulcerative colitis. Zeposia targets the sphingosine-1-phosphate (S1P) receptor, just like Arena's etrasimod. Typically, good data from a rival drugmaker would send shares down, not up, but ulcerative colitis is a common enough disease -- around a million Americans have it -- that there's enough room in the marketplace for more than one drug.